Thus, by generating an artificial gradient of these ligands in the microfluidic device we have demonstrated that both SAA1 and to a lesser extent, RSPO3, can drive glioma tumor cell chemotactic invasion. This evidence concerns the gene RSPO3 and central nervous system cancer.